TABLE 5.

GLM Estimates of Post-Index Second Year All-Cause and OP-Related Total Costs

	All-Cause Total Costs			OP-Related Total Costs
	Costs	SE	P Valuea	Costs	SE	P Valuea
Complianceb (No as reference)	0.97	1.03	0.298	0.91	1.04	0.007
Age (aged < 65 years as reference)	0.73	1.01	< 0.001	0.90	1.02	< 0.001
Geographic region (Northeast as reference)
Midwest	0.80	1.02	< 0.001	0.96	1.03	0.180
South	0.81	1.02	< 0.001	0.85	1.03	< 0.001
West	0.92	1.02	0.001	1.05	1.03	0.162
Health plan type (HMO as reference)
PPO	0.83	1.02	< 0.001	0.73	1.03	< 0.001
Other	0.98	1.02	0.299	1.01	1.03	0.802
Pre-index osteoporosis	0.97	1.01	0.045	1.14	1.02	< 0.001
Pre-index comorbidities
Deyo-Charlson Comorbidity Score	1.30	1.01	< 0.001	1.05	1.01	< 0.001
Inflammatory bowel disease	1.62	1.07	< 0.001	1.59	1.11	< 0.001
Rheumatoid arthritis	1.73	1.03	< 0.001	1.50	1.05	< 0.001
Asthma	1.35	1.03	< 0.001	1.01	1.04	0.779
Stroke	0.91	1.03	0.001	0.87	1.04	0.001
COPD	1.16	1.03	< 0.001	1.37	1.04	< 0.001
Index medication (Alendronate as reference)
Renal disease	0.91	1.04	0.023	1.18	1.06	0.006
Risedronate	1.04	1.02	0.005	1.51	1.02	< 0.001
Ibandronate	1.16	1.02	< 0.001	1.59	1.03	< 0.001
Discontinued	1.01	1.03	0.740	1.02	1.04	0.637

^a P values ≤ 0.05 are italicized.

^b Patients with MPR ≥ 70% were considered compliant.

COPD = chronic obstructive pulmonary disease; GLM = generalized linear models; HMO = health maintenance organization; MPR = medication possession ratio; OP = osteoporosis; PPO = preferred provider organization; SE = standard error.